November 17, 2021 News by Marisa Wexler, MS Vumerity Approved for RRMS in European Union The oral medication Vumerity (diroximel fumarate) has been approved by the European Commission to treat adults with relapsing-remitting multiple sclerosis (RRMS). “This approval is a significant step forward in improving treatment adherence for people living with relapsing MS, which can make a meaningful difference on treatment…
September 20, 2021 News by Marisa Wexler, MS Vumerity Recommended for EU Approval as RRMS Treatment A committee of the European Medicines Agency is recommending that Vumerity (diroximel fumarate) be approved as an oral treatment for adults with relapsing-remitting multiple sclerosisĀ (RRMS) in the European Union. The opinion, from the agency’s Committee for Medicinal Products for Human Use (CHMP), will now be sent…
April 28, 2021 News by Forest Ray PhD #AANAM ā Vumerity Showing Tolerability, Efficacy in Ongoing EVOLVE-MS-1 Trial Editorās note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17ā22. GoĀ hereĀ to read the latest stories from the conference. Vumerity (diroximel fumarate) continues to be safe and well-tolerated, in addition to reducing measures of disease activity in people…
May 20, 2020 News by Marisa Wexler, MS Biogen Presents Update on its MS Therapeutic Portfolio Biogen has released new data on several of its therapies for multiple sclerosis (MS), including Vumerity (diroximel fumarate), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab). The data ā six presentations ā originally were to be presented at the 2020 annual conference of the American…
June 4, 2019 News by Patricia Inacio, PhD Vumerity’s Safety, Effectiveness Bolstered by New Data from EVOLVE-MS-1 Trial Vumerity (diroximel fumarate), taken as a 462 milligram (mg) tablet twice daily, significantly decreases disease activity in patients withĀ relapsing-remitting multiple sclerosisĀ (RRMS), and leads to low rates of gastrointestinal side effects, new interim data of Phase 3 trial EVOLVE-MS-1 show. The findings were presented at the 2019 Consortium…
April 25, 2018 News by Patricia Inacio, PhD #AAN2018 ā ALKS 8700Ā Shows Promise as RRMS Therapy, Phase 3 Trial Interim Results Suggest A one-year analysis of the ongoing Phase 3 EVOLVE-MS-1 trial of ALKS 8700Ā as a therapy for relapsing remitting multiple sclerosis (RRMS) supports the experimental therapy’s effectiveness, with the treatment significantly reducing the number of MS lesions. Interim results from the trial were presented Tuesday at the…